Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4241-4249

  Mohamed, Ami F ^a,b   Karaiskos, Ilias ^c   Plachouras, Diamantis ^c   Karvanen, Matti ^a   Pontikis, Konstantinos ^c   Jansson, Britt ^a   Papadomichelakis, Evangelos ^c   Antoniadou, Anastasia ^c   Giamarellou, Helen ^c   Armaganidis, Apostolos ^c   Cars, Otto ^a   Friberg, Lena E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIALYSIS; DRUG BINDING; DRUG HALF LIFE; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTH PROGRAM; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NECROTIZING FASCIITIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA;

EID: 84864386288     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06426-11     Document Type: Article

References (39)

1. Ainsworth GC, Brown AM, Brownlee G. 1947. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 159:263.
2. Bergen PJ, et al. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789.
3. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
4. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
5. Couet W, et al. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89:875-879.
6. Reference deleted.
7. Craig WA, Kunin CM. 1976. Significance of serum protein and tissue binding of antimicrobial agents. Annu. Rev. Med. 27:287-300.
8. Deryke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54:4503-4505.
9. Dudhani RV, Li J, Nation RL. 2009. Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications, abstr A1-576. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Dudhani RV, Nation RL, Li J. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J. Antimicrob. Chemother. 65:1412-1415.
11. Dudhani RV, et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
12. European Committee on Antimicrobial Susceptibility Testing. 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland. http://www.eucast.org.
13. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. (Pubitemid 40570245)
14. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10:R27.
15. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
16. Harbarth S, et al. 2003. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115:529-535. (Pubitemid 37352798)
17. Harris DC. 1998. Nonlinear least-squares curve fitting with microsoft Excel solver. Comput. Bulletin Board 75:119-121. (Pubitemid 128590127)
18. Imberti R, et al. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339.
19. Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. 2009. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J. Pharm. Biomed. Anal. 49:760-767.
20. Jonsson EN, Karlsson MO. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
21. Karlsson MO, Beal SL, Sheiner LB. 1995. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharm. 23:651-672. (Pubitemid 26155338)
22. Karrlson MO, Holford N. 2008. A tutorial on visual predictive checks, abstr 1434. Abstr. Annu. Meet. Popul. Approach Group, Marseille, France. http://www.page-meeting.org/?abstr=1434.
23. Koyama Y, et al. 1950. A new antibiotic 'colistin' produced by sporeforming soil bacteria. J. Antibiot. (Tokyo) 3:457-458.
24. Li J, et al. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46:3304-3307.
25. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
26. Lim LM, et al. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291.
27. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257. (Pubitemid 41196689)
28. Matthews I, Kirkpatrick C, Holford N. 2004. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br. J. Clin. Pharmacol. 58:8-19. (Pubitemid 38901461)
29. Mohamed A, Cars O, Friberg LE. 2011. Pharmacokinetic-pharmacodynamic modeling of pre-existing and emerging resistance of Pseudomonas aeruginosa to colistin, p 20, abstr 2223. Abstr. Annu. Meet. Popul. Approach Group, Athens, Greece. www.page-meeting.org/?abstr=2223.
30. Mohamed AF, Nielsen EI, Cars O, Friberg LE. 2012. Pharmacokineti- cpharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob. Agents Chemother. 56:179-188.
31. Nielsen EI, Cars O, Friberg LE. 2011. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob. Agents Chemother. 55:4619-4630.
32. Nielsen EI, et al. 2007. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob. Agents Chemother. 51:128-136. (Pubitemid 46047697)
33. Orwa JA, et al. 2001. Isolation and structural characterization of colistin components. J. Antibiot. (Tokyo) 54:595-599. (Pubitemid 32737498)
34. Plachouras D, et al. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53:3430-3436.
35. Pogue JM, et al. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53:879-884.
36. Raghavan M, Marik PE. 2006. Management of sepsis during the early "golden hours." J. Emerg. Med. 31:185-199. (Pubitemid 44302056)
37. Spapen H, Van Gorp JRV, Troblelyn J, Honore PM. 2011. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 1:14.
38. Stansly PG, Shepherd RG, White HJ. 1947. Polymyxin: a new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 81:43-54.
39. Wahlby U, Thomson AH, Milligan PA, Karlsson MO. 2004. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br. J. Clin. Pharmacol. 58:367-377. (Pubitemid 39312460)